Clinical Trial Update: Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) [Phase 1]

View source ↗

Summary

Update on the Phase 1 study of HPN217 (MK-4002-001) for relapsed/refractory multiple myeloma, indicating the trial remains active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• HPN217

Snippet

Sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Multiple Myeloma in Relapse, Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING